Cook MyoSite
Cook MyoSite is a Pittsburgh-based cellular technology subsidiary of Cook Group that develops the investigational iltamiocel autologous muscle-derived cell therapy (in Phase III trials for incontinence and dysphagia) and sells research cell products, media, and contract services to academic, pharmaceutical, and biotech researchers worldwide.
- Company typePrivate
- Founded2002
- HeadquartersPennsylvania Furnace, United States
- Headcount101–250
- GTM type—
- Offering—
What Cook MyoSite does
Cook MyoSite, Inc. is a clinical-stage cellular technology company and a wholly owned subsidiary of Cook Group, founded in 2002 and headquartered in Pittsburgh, Pennsylvania. The company operates two integrated business lines built on a single underlying platform: (1) clinical development of iltamiocel, an investigational autologous muscle-derived cell (AMDC) therapy that harvests, processes, and reinjects a patient's own muscle cells to treat muscle dysfunction, with lead programs in Phase III trials for fecal incontinence (DigniFI study) and stress urinary incontinence (CELLEBRATE study), plus earlier-stage work in underactive bladder and oropharyngeal dysphagia; and (2) Custom Cell Solutions, which sells and contract-manufactures highly characterized primary human skeletal muscle-derived cells (skMDC), the first and only commercial purified human fibro-adipogenic progenitor (FAP) cells, the MyoTonic family of culture media, the MyoBridge volunteer donor tissue-sourcing program, and research contract services (custom manufacturing, cryopreservation, donor procurement, analytical testing, and assay development) under an ISO9001:2015-certified quality system.
The company's core technology is its AMDC platform, with proprietary processes for isolating, expanding, and characterizing muscle-derived cells across two Pittsburgh facilities totaling over 10,000 sq ft of laboratory space, including 3,400+ sq ft of ISO 7 and ISO 5 cleanroom capacity. The FDA has granted three Regenerative Medicine Advanced Therapy (RMAT) designations to iltamiocel across separate indications (2020, 2022, 2024), providing accelerated regulatory pathways and third-party validation of the platform.
Revenue is generated primarily through (a) one-time sales of research cell products, media, and catalog consumables to academic, pharmaceutical, and biotechnology research customers; (b) professional services revenue from custom contract research, tissue sourcing (MyoBridge), and analytical work; and (c) future clinical revenue from iltamiocel commercialization, which remains pre-revenue. Go-to-market is direct enterprise sales supported by product specialists and global cold-chain logistics, with quote-based (non-publicly-disclosed) pricing. Customers are concentrated in three horizontal segments: academic researchers and institutions, pharmaceutical and biotechnology companies, and CROs supporting clinical development. The company employs 101-250 people, is led by Carl Cook (CEO of Cook Group and President of Cook MyoSite) with Ryan Pruchnic as Managing Vice President and Site Head, and is governed under Indiana corporate law as part of the privately held Cook Group conglomerate.
Cook MyoSite firmographics
Firmographics- Name
- Cook MyoSite
- Legal name
- Cook MyoSite, Inc.
- Website
- https://cookmyosite.com
- Company type
- Private
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Cook MyoSite is a Pittsburgh-based cellular technology subsidiary of Cook Group that develops the investigational iltamiocel autologous muscle-derived cell therapy (in Phase III trials for incontinence and dysphagia) and sells research cell products, media, and contract services to academic, pharmaceutical, and biotech researchers worldwide.
- Ownership category
- akta.pro rank
Cook MyoSite industry classification
Industry- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables) (HLAAABAH)
- akta.pro secondary industries
- Cell Therapy CDMO (Autologous/Allogeneic Manufacturing) (HLAGAGAA), Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC)
Keywords
Where Cook MyoSite is headquartered
LocationHeadquarters
- HQ city
- Pennsylvania Furnace
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Cook MyoSite business model
Business modelRevenue model
- Cell Therapy Clinical Development: Cook MyoSite is advancing iltamiocel through Phase III clinical trials for multiple indications including fecal incontinence (DigniFI study) and stress urinary incontinence (CELLEBRATE study). Revenue will be generated upon regulatory approval and commercialization of the cell therapy product.
- Custom Cell Solutions - Research Products: Sale of primary human skeletal muscle-derived cells (skMDC), FAP cells, and specialized media products to academic researchers and pharmaceutical companies for preclinical research applications.
- Research Contract Services: Customized contract research services including muscle and adherent cell production, cryopreservation, manufacturing process development, procurement from specific donor populations, custom media formulations, and QC analytical testing.
- MyoBridge Tissue Sourcing: Tissue sourcing program providing human muscle samples from stratified donor populations with end-to-end service from donor recruitment through cold-chain delivery.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Cook MyoSite product offering
Product offeringCore offering
Cook MyoSite develops and commercializes muscle-derived cell technologies through two business lines: (1) clinical-stage development of iltamiocel, an investigational autologous muscle-derived cell therapy in Phase III trials for stress urinary incontinence, fecal incontinence, and oropharyngeal dysphagia; and (2) Custom Cell Solutions, providing primary human skeletal muscle-derived cells (skMDC), fibro-adipogenic progenitor (FAP) cells, MyoTonic/CryoTonic culture media, the MyoBridge donor tissue program, and contract research services to academic and pharmaceutical researchers globally.
Product overview
Cook MyoSite is a clinical-stage biopharmaceutical company and research products provider focused on muscle cell technology. The company operates two primary business lines: (1) Clinical Development of iltamiocel, an investigational autologous muscle-derived cell (AMDC) therapy platform in Phase III trials for stress urinary incontinence, fecal incontinence, underactive bladder, and oropharyngeal dysphagia; and (2) Custom Cell Solutions providing research products including skeletal muscle-derived cells (skMDC), fibro-adipogenic progenitor (FAP) cells, MyoTonic and CryoTonic culture media, the MyoBridge tissue donor program, and contract research services. All laboratory research services are manufactured under an ISO9001:2015 Certified Quality Management System. The company operates GMP-qualified facilities with over 3,400 square feet of cleanroom space in Pittsburgh, Pennsylvania.
Differentiator
Problem solved
Functional benefit
Brands
- MyoBridge: A volunteer donor program for sourcing human muscle tissue and primary cells from precisely defined donor groups, enabling researchers to access unrivaled characterization and simplify tissue sourcing.
- MyoTonic
- Iltamiocel
Quantifiable outcome
- First participant treated in DigniFI Phase III trial for fecal incontinence (August 2024)
- +3 more outcomes
Companies that use Cook MyoSite
Customer profileNamed customers1 record
Segments3 records
Cook MyoSite technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Cook MyoSite partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- VeristatcorePartnership to support the DigniFI Study, a Phase III clinical trial evaluating iltamiocel cell therapy for chronic fecal incontinence in women with obstetric anal sphincter injury history. The partnership achieved a key milestone by activating 26 trial sites and enrolling more than 100 participants with over 95% study adherence.
- Curi BiocoreStrategic scientific collaboration to develop advanced, predictive human engineered tissue models for muscle-related diseases and metabolic disorders. Curi Bio integrates its Mantarray 3D tissue engineering platform with Cook MyoSite's primary human myoblasts and FAP cells to produce physiologically relevant tissue models for studying sarcopenia, diabetes, obesity, neuromuscular disorders, and diseases responsive to GLP-1 therapies. The resulting tissue models are commercially available immediately.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
Cook MyoSite competitors and assessment
Company assessmentBroad incumbents
- Lonza: Global cell therapy CDMO offering autologous and allogeneic manufacturing services for clinical and commercial cell therapies. Comparable to Cook MyoSite's biomanufacturing services and cell therapy manufacturing capabilities, but at vastly larger scale and across many cell types beyond muscle.
- Catalent (Paragon Gene Therapy / cell therapy): Major CDMO providing cell therapy development and manufacturing services, including autologous cell processing for clinical and commercial supply. Directly comparable in providing outsourced manufacturing capacity for autologous cell therapies like iltamiocel.
- Thermo Fisher Scientific (Gibco / Cell Therapy Services): Diversified life sciences leader offering Gibco cell culture media, primary cells, and contract cell therapy manufacturing services. Comparable to Cook MyoSite on both the media/reagent side (MyoTonic) and the cell therapy manufacturing side.
- Bio-Techne: Provides primary cells, cell culture media, and reagents for research and cell therapy applications, including muscle and stem cell biology. Directly comparable to Cook MyoSite's Custom Cell Solutions product line (skMDC, MyoTonic media, FAP cells) for research customers.
- MilliporeSigma (Sigma-Aldrich, Merck KGaA Life Science): Major supplier of cell culture media, primary cells, and bioprocessing solutions for cell therapy and regenerative medicine research. Comparable to Cook MyoSite's media products (MyoTonic/CryoTonic) and broader research products portfolio.
- Cytiva: Provides cell therapy manufacturing technologies, media, and services across autologous and allogeneic platforms. Comparable to Cook MyoSite on the bioprocessing tools, media, and cell therapy manufacturing infrastructure side.
Direct peers
- Cellular Dynamics International (Fujifilm CDI): Supplier of human primary cells and iPSC-derived cell products for research, drug discovery, and cell therapy development. Directly comparable to Cook MyoSite's Custom Cell Solutions business providing characterized primary cells to researchers and pharmaceutical companies.
- ATCC: Global biological resource center providing authenticated cell lines, primary cells, and reagents for research. Comparable to Cook MyoSite's MyoBridge donor program and primary muscle cell offerings to the academic and pharma research market.
- PromoCell: Supplier of primary human cells, including skeletal muscle myoblasts, along with specialized media for cell culture research. Directly comparable to Cook MyoSite's skMDC cells and muscle-focused research products catalog.
Emerging players
- RoosterBio: Emerging supplier of primary human mesenchymal stem cells and bioprocessing media targeting cell therapy and regenerative medicine developers. Comparable business model to Cook MyoSite's Custom Cell Solutions focus on enabling cell therapy development through high-quality cellular inputs.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Cook MyoSite social profiles
Digital presenceCook MyoSite compliance and trust
Trust signalCompliance1 record
Cook MyoSite financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cook MyoSite leadership team
Management profileNumber of profiles
Cook MyoSite funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cook MyoSite M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cook MyoSite
What does Cook MyoSite do?
Cook MyoSite develops and commercializes muscle-derived cell technologies through two business lines: (1) clinical-stage development of iltamiocel, an investigational autologous muscle-derived cell therapy in Phase III trials for stress urinary incontinence, fecal incontinence, and oropharyngeal dysphagia; and (2) Custom Cell Solutions, providing primary human skeletal muscle-derived cells (skMDC), fibro-adipogenic progenitor (FAP) cells, MyoTonic/CryoTonic culture media, the MyoBridge donor tissue program, and contract research services to academic and pharmaceutical researchers globally.
Is Cook MyoSite a public or private company?
Cook MyoSite is a private company. It is currently operating.
When was Cook MyoSite founded?
Cook MyoSite was founded in 2002. It employs 101 to 250 people.
Where is Cook MyoSite based?
Cook MyoSite is headquartered in Pennsylvania Furnace, United States, in the North America region.
How does Cook MyoSite make money?
Four revenue lines are on record. Cell Therapy Clinical Development is the primary driver. The others are custom Cell Solutions - Research Products, research Contract Services and myoBridge Tissue Sourcing.
Who are Cook MyoSite's main competitors?
Broad incumbents on record are Lonza, Catalent (Paragon Gene Therapy / cell therapy), Thermo Fisher Scientific (Gibco / Cell Therapy Services), Bio-Techne, MilliporeSigma (Sigma-Aldrich, Merck KGaA Life Science) and Cytiva. Direct peers are Cellular Dynamics International (Fujifilm CDI), ATCC and PromoCell. RoosterBio is listed as an emerging player.
Does Cook MyoSite have an API?
No public API is recorded for Cook MyoSite.
What industry is Cook MyoSite in?
Its primary akta.pro industry code is HLAAABAH, Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables), with a secondary code of HLAGAGAA, Cell Therapy CDMO (Autologous/Allogeneic Manufacturing). Its NAICS code is 325414 and its SIC code is 8731.